Press Releases

03/12/2018

A robust method to study cancer heterogeneity in liquid biopsy

Copy Number Alteration Profiling of Single Circulating Tumor Cells which May Be used to Predict Response to Therapy

continue →

Topics: CTCs, DEPArray NxT, NGS, CELLSEARCH, Liquid biopsy, Precision Medicine, low-pass, copy number alteration

05/16/2017

Top International Experts Gather to Understand the Many Faces of Cancer

Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington

continue →

Topics: FFPE, CTCs, Liquid biopsy, International experts, Menarini International Foundation, Precision Medicine, Cancer Heterogeneity, International conference

04/3/2017

Menarini-Silicon Biosystems Completes Acquisition of CELLSEARCH® Assets

Liquid Biopsy Test for Circulating Tumor Cells Marks Its First Entry into U.S. Diagnostics Market

continue →

Topics: CTCs, deparray, CELLSEARCH, acquisition, CTC test, Liquid biopsy

12/20/2016

Menarini-Silicon Biosystems to Acquire CELLSEARCH® CTC System

Only FDA-Cleared CTC test to join Company’s Portfolio of Diagnostics

continue →

Topics: CTCs, single-cell isolation, deparray, CELLSEARCH

11/25/2016

DEPArray™ Single-Cell Isolation Technology Enables Researchers to Develop a Model for Predicting Response to Treatment in Patients with Lung Cancer

Genetic Profiles of Circulating Tumor Cells May Predict Drug Resistance and Clinical Outcomes

continue →

Topics: CTCs, lung cancer, deparray, SCLC

Ask Us a QuestionShare your DEPArray™ storySubscribe to newsletter